Completed PHASE4 INTERVENTIONAL 2-arm NCT01303601

Efficacy of Olanzapine Monotherapy for Treatment Bipolar Ⅰ Depression

Efficacy of Olanzapine Monotherapy for Treatment Bipolar Ⅰ Depression: a Randomized, Double-blind, Placebo Controlled Study

Sponsor: China Medical University, China

Conditions Bipolar Disorder Depression, Bipolar

Interventions Starch olanzapine

Updated 4 times since 2017 Last updated: Feb 24, 2011 Started: Jan 31, 2009 Completion: Oct 31, 2010

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT01303601, this PHASE4 trial focuses on Bipolar Disorder and Depression, Bipolar and remains completed. Sponsored by China Medical University, China, it has been updated 4 times since 2009, reflecting limited change activity. Mental health research at this phase helps define safety and dosing parameters for future study.

Status Flow

Change History

4 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE4
Jul 2024 — Sep 2024 [monthly]

Completed PHASE4
Jan 2021 — Jul 2024 [monthly]

Completed PHASE4
Jan 2017 — Jan 2021 [monthly]

Completed PHASE4

First recorded

Jan 2009

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

China Medical University, China

Data source: China Medical University, China

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Shenyang, China